1
|
Pistone M, Racaniello GF, Rizzi R, Iacobazzi RM, Arduino I, Lopalco A, Lopedota AA, Denora N. Direct cyclodextrin based powder extrusion 3D printing of budesonide loaded mini-tablets for the treatment of eosinophilic colitis in paediatric patients. Int J Pharm 2023; 632:122592. [PMID: 36626971 DOI: 10.1016/j.ijpharm.2023.122592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 01/04/2023] [Accepted: 01/05/2023] [Indexed: 01/08/2023]
Abstract
The purpose of this study was to combine direct powder extrusion (DPE) 3D printing and fluid bed coating techniques to create a budesonide (BD) loaded solid oral formulations for the treatment of eosinophilic colitis (EC) in paediatric patients. The preferred medication for EC treatment is BD, which has drawbacks due to its poor water solubility and low absorption. Additionally, since commercially available medications for EC treatment are created and approved for adult patients, administering them to children sometimes requires an off-label use and an impromptu handling, which can result in therapeutic ineffectiveness. The DPE 3D approach was investigated to create Mini-Tablets (MTs) to suit the swallowing, palatability, and dose flexibility control requirements needed by paediatric patients. Additionally, DPE 3D and the inclusion of hydroxypropyl-β-cyclodextrin in the initial powder mixture allowed for an improvement in the solubility and rate of BD dissolution in aqueous medium. Then, to accomplish a site-specific drug release at the intestinal level, MTs were coated with a layer of Eudragit FS 30D, an enteric polymer responsive at pH > 7.0 values. In vitro release experiments showed that film-coated MTs were suitable in terms of size and dose, enabling potential therapeutic customization and targeted delivery of BD to the colon.
Collapse
Affiliation(s)
- Monica Pistone
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | | | - Rosanna Rizzi
- Institute of Crystallography-CNR, Amendola St. 122/o, 70126 Bari, Italy
| | - Rosa Maria Iacobazzi
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | - Ilaria Arduino
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | - Antonio Lopalco
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy
| | - Angela Assunta Lopedota
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy.
| | - Nunzio Denora
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona St. 4, 70125 Bari, Italy.
| |
Collapse
|
2
|
Takano R, Maurer R, Jacob L, Stowasser F, Stillhart C, Page S. Formulating Amorphous Solid Dispersions: Impact of Inorganic Salts on Drug Release from Tablets Containing Itraconazole-HPMC Extrudate. Mol Pharm 2019; 17:2768-2778. [DOI: 10.1021/acs.molpharmaceut.9b01109] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Ryusuke Takano
- Pharmaceutical Research and Development, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland
- Discovery Technology Department, Chugai Pharmaceutical Co., Ltd, Shizuoka 412-8513, Japan
| | - Reto Maurer
- Pharmaceutical Research and Development, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland
| | - Laurence Jacob
- Pharmaceutical Research and Development, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland
| | - Frank Stowasser
- Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland
| | - Cordula Stillhart
- Pharmaceutical Research and Development, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland
| | - Susanne Page
- Pharmaceutical Research and Development, F. Hoffmann-La Roche Ltd, Basel 4070, Switzerland
| |
Collapse
|
3
|
Ditzinger F, Price DJ, Ilie AR, Köhl NJ, Jankovic S, Tsakiridou G, Aleandri S, Kalantzi L, Holm R, Nair A, Saal C, Griffin B, Kuentz M. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches – a PEARRL review. J Pharm Pharmacol 2018; 71:464-482. [DOI: 10.1111/jphp.12984] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 06/27/2018] [Indexed: 11/30/2022]
Abstract
Abstract
Objectives
This review highlights aspects of drug hydrophobicity and lipophilicity as determinants of different oral formulation approaches with specific focus on enabling formulation technologies. An overview is provided on appropriate formulation selection by focussing on the physicochemical properties of the drug.
Key findings
Crystal lattice energy and the octanol–water partitioning behaviour of a poorly soluble drug are conventionally viewed as characteristics of hydrophobicity and lipophilicity, which matter particularly for any dissolution process during manufacturing and regarding drug release in the gastrointestinal tract. Different oral formulation strategies are discussed in the present review, including lipid-based delivery, amorphous solid dispersions, mesoporous silica, nanosuspensions and cyclodextrin formulations.
Summary
Current literature suggests that selection of formulation approaches in pharmaceutics is still highly dependent on the availability of technological expertise in a company or research group. Encouraging is that, recent advancements point to more structured and scientifically based development approaches. More research is still needed to better link physicochemical drug properties to pharmaceutical formulation design.
Collapse
Affiliation(s)
- Felix Ditzinger
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Daniel J Price
- Analytics Healthcare, Merck KGaA, Darmstadt, Germany
- Goethe University, Frankfurt, Germany
| | - Alexandra-Roxana Ilie
- School of Pharmacy, University College Cork, Cork, Ireland
- Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium
| | - Niklas J Köhl
- School of Pharmacy, University College Cork, Cork, Ireland
| | - Sandra Jankovic
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Georgia Tsakiridou
- Product Design & Evaluation, Pharmathen SA, Athens, Greece
- Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
| | - Simone Aleandri
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| | - Lida Kalantzi
- Product Design & Evaluation, Pharmathen SA, Athens, Greece
| | - René Holm
- Drug Product Development, Janssen Research and Development, Johnson and Johnson, Beerse, Belgium
| | - Anita Nair
- Analytics Healthcare, Merck KGaA, Darmstadt, Germany
| | | | | | - Martin Kuentz
- Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
| |
Collapse
|